Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - gonal
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpdd18b3b8f2dba9230f63c60b0e5cbf28
identifier: http://ema.europa.eu/identifier
/EU/1/95/001/025
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: GONAL-f 75 IU powder and solvent for solution for injection
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-dd18b3b8f2dba9230f63c60b0e5cbf28
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/95/001/025
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - gonal
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
How to prepare and use the GONAL-f powder and solvent
What is in this leaflet
What GONAL-f is
GONAL-f contains a medicine called follitropin alfa . Follitropin alfa is a type of follicle stimulating hormone (FSH) which belongs to the family of hormones called gonadotropins . Gonadotropins are involved in reproduction and fertility.
What GONAL-f is used for
In adult women, GONAL-f is used:
In adult men, GONAL-f is used:
You and your partner s fertility should be evaluated before the treatment is started by a doctor experienced in treating fertility disorders.
Do not use GONAL-f
Do not use GONAL-f if any of the above applies to you. If you are not sure, talk to your doctor before using this medicine.
Warnings and precautions
Talk to your doctor, pharmacist or nurse before using Gonal-f.
Porphyria
Tell your doctor before you start treatment, if you or any member of your family have porphyria (an inability to break down porphyrins that may be passed on from parents to children).
Tell your doctor straight away if:
In case of the above events your doctor may recommend that you stop treatment.
Ovarian hyper-stimulation syndrome (OHSS)
If you are a woman, this medicine increases your risk of developing OHSS. This is when your follicles develop too much and become large cysts. If you get lower abdominal pain, gain any weight rapidly, feel sick or are vomiting or if you have difficulty in breathing, talk to your doctor straight away who might ask you to stop using this medicine (see section 4). In case you are not ovulating, and if the recommended dose and schedule of administration are adhered to, the occurrence of OHSS is less likely. GONAL-f treatment seldom causes severe OHSS unless the medicine that is used for final follicular maturation (containing human chorionic gonadotropin, hCG) is administered. If you are developing OHSS your doctor may not give you any hCG in this treatment cycle and you may be told not to have sex or to use a barrier contraceptive method for at least four days.
Multiple pregnancy
When using GONAL-f, you have a higher risk of being pregnant with more than one child at the same time ( multiple pregnancy , mostly twins), than if you conceived naturally. Multiple pregnancy may lead to medical complications for you and your babies. You can reduce the risk of multiple pregnancy by using the right dose of GONAL-f at the right times. When undergoing assisted reproductive technology, the risk of having a multiple pregnancy is related to your age, the quality and the number of fertilised eggs or embryos placed inside you.
Miscarriage
When undergoing assisted reproductive technology or stimulation of your ovaries to produce eggs, you are more likely to have a miscarriage than the average woman.
Blood clotting problems (thromboembolic events)
If you had in the past or recently blood clots in the leg or in the lung, or a heart attack or stroke, or if those happened in your family, then you might have a higher risk that these problems occur or become worse with GONAL-f treatment.
Men with too much FSH in their blood
If you are a man, having too much FSH in your blood can be a sign of damaged testicles. GONAL-f usually does not work if you have this problem.
If your doctor decides to try GONAL-f treatment, to monitor the treatment, they may ask you to provide semen for analysis 4 to 6 months after starting treatment.
Children and adolescents
GONAL-f is not for use in children and adolescents below 18 years old.
Other medicines and GONAL-f
Tell your doctor if you are taking, have recently taken or might take any other medicines.
Pregnancy and breast-feeding
Do not use GONAL-f if you are pregnant or breast-feeding.
Driving and using machines
It is not expected that this medicine will affect your ability to drive and use machines.
GONAL-f contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per dose that is to say essentially sodium-free .
Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Using this medicine
How much to use
Your doctor will decide how much medicine you will take and how often. The doses described below are stated in International Units (IU).
Women
If you are not ovulating and have irregular or no periods.
If your doctor cannot see a desired response after 4 weeks, that treatment cycle with GONAL-f should be stopped. For the following treatment cycle, your doctor will give you a higher starting dose of GONAL-f than before.
If your body responds too strongly, your treatment will be stopped and you will not be given any hCG (see section 2, Ovarian hyper-stimulation syndrome (OHSS) ). For the following cycle, your doctor will give you a lower dose of GONAL-f than before.
If you have been diagnosed with very low levels of FSH and LH hormones
If your doctor cannot see a response after 5 weeks, that treatment cycle with GONAL-f should be stopped. For the following cycle, your doctor will give you a higher starting dose of GONAL-f than before. If your body responds too strongly, your treatment with GONAL-f will be stopped and you will not be given any hCG (see section 2, Ovarian hyper-stimulation syndrome (OHSS) ). For the following cycle, your doctor will give you a lower dose of GONAL-f than before. If you need to develop several eggs for collection prior to any assisted reproductive technology
In other cases, your doctor may first stop you from ovulating by using a gonadotropin-releasing hormone (GnRH) agonist or antagonist. Then GONAL-f is started approximately two weeks after start of agonist treatment. The GONAL-f and GnRH agonist are then both given until your follicles develop as desired. For example, after two weeks of GnRH agonist treatment, 150 to 225 IU GONAL-f is administered for 7 days. The dose is then adjusted according to your ovarian response.
Men
If you use more GONAL-f than you should
The effects of taking too much GONAL-f are unknown. Nevertheless, one could expect ovarian hyper- stimulation syndrome (OHSS) to occur, which is described in section 4. However, the OHSS will only occur if hCG is also administered (see section 2, Ovarian hyper-stimulation syndrome (OHSS) ).
If you forget to use GONAL-f
If you forget to use GONAL-f, do not take a double dose to make up for a forgotten dose. Please talk to your doctor as soon as you notice that you forgot a dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects in women
Serious side effects in men and women
If you notice any of the above-listed side effects, you should immediately contact your doctor who might ask you to stop using GONAL-f.
Other side effects in women
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Very rare (may affect up to 1 in 10 000 people):
Other side effects in men
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Very rare (may affect up to 1 in 10 000 people):
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the vial after EXP. The expiry date refers to the last day of that month.
Do not store above 25 C.
Store in the original package, in order to protect from light.
Do not use GONAL-f if you notice any visible signs of deterioration, if the liquid contains particles or is not clear.
The medicine must be administered immediately after preparation.
Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
GONAL-f should not be administered as a mixture with other medicines in the same injection, except for lutropin alfa. Studies have shown that these two medicines can be mixed and injected together, without either product being adversely affected.
What GONAL-f contains
What GONAL-f looks like and contents of the pack
Marketing Authorisation Holder
Merck Europe B.V., Gustav Mahlerplein 102, 1082 MA Amsterdam, The Netherlands
Manufacturer
Merck Serono S.p.A., Via delle Magnolie 15, 70026 Modugno (Bari), Italy
This leaflet was last revised in {MM/YYYY}. Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-dd18b3b8f2dba9230f63c60b0e5cbf28
Resource Composition:
Generated Narrative: Composition composition-en-dd18b3b8f2dba9230f63c60b0e5cbf28
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/95/001/025status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - gonal
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpdd18b3b8f2dba9230f63c60b0e5cbf28
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpdd18b3b8f2dba9230f63c60b0e5cbf28
identifier:
http://ema.europa.eu/identifier
/EU/1/95/001/025type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: GONAL-f 75 IU powder and solvent for solution for injection
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en